Information Provided By:
Fly News Breaks for February 26, 2020
GWPH
Feb 26, 2020 | 07:35 EDT
Oppenheimer analyst Esther Rajavelu lowered her price target for GW Pharmaceuticals to $173 from $203 following Q4 results and 2020 expense guidance. Following a year of "solid" commercial execution in 2019, Rajavelu expects 2020 momentum from both commercial execution and clinical/regulatory catalysts. At current trading levels, she continues to view GW Pharmaceuticals as an "attractive investment opportunity." The analyst maintains an Outperform rating on the shares.
News For GWPH From the Last 2 Days
There are no results for your query GWPH